In an attempt to rationally design new drugs for trypanosomiasis, we have been exploring ways to increase in trypanosomes the amount of oxidant stress or the sensitivity to oxidants. Our studies have included ways to generate free radicals in the trypanosome and the nature of the enzymes that trypanosomes have to combat oxidant stress. During the previous grant period, we have investigated the following: 1) A large series of quinone derivatives were synthesized and found to be trypanocidal in vitro but without any activity in vivo. Attempts to modify the structure to prevent metabolism were without success. 2) T. brucei, T. cruzi, C. fasciculata, L. tropica were found to have an iron-containing superoxide dismutase (SOD) in contrast to the Cu, Zn-SOD and Mn-SOD found in mammalian cells. A difference in sensitivity to various inhibitors points to the potential of being able to selectively interfere with this crucial enzyme. 3) In contrast to the GSH reductase from all other organisms previously studied, the trypanosomal enzyme had an obligate requirement for a novel thiol-containing co-factor. The structure of this co-factor, trypanothione, has been recently elucidated and found to be bis-(glutathionyl) spermidine. Since trypanothione is present in all the parasitic trypanosomes, e.g. T. brucei, T. cruzi, L. mexicana and not in other organisms, it offers a unique point of attack for chemotherapeutic intervention. Accordingly, in the next grant period, we will concentrate on this new finding. 1) Further chemical and biochemical studies of trypanothione are planned in order to gain new insight in the conformation of the molecule. These are being pursued so that new agents can be designed which will react to inactivate the co-factor. 2) Trypanothione reductase from C. fasciculata and T. brucei will be isolated and studied so that new agents can be designed and synthesized to inhibit this key enzyme. 3) The biosynthesis of trypanothione also offers a point of attack. Spermidine analogues will be evaluated as potential agents. Hopefully, these studies will give new insight into drug design for trypanosomiasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AI019428-13
Application #
2060927
Study Section
Special Emphasis Panel (NSS)
Project Start
1991-03-01
Project End
1996-02-29
Budget Start
1994-03-01
Budget End
1995-02-28
Support Year
13
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Picower Institute for Medical Research
Department
Type
DUNS #
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Berger, B J; Suskin, M; Dai, W W et al. (1997) Studies on the pharmacological properties of novel arylene bis(methylketone) compounds using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 691:433-40
Berger, B J; Dai, W W; Cerami, A et al. (1997) Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone). Biochem Pharmacol 54:739-42
Berger, B J; Paciorkowski, A; Suskin, M et al. (1996) Antimalarial activity of novel arylene bis(methylketone) compounds. J Infect Dis 174:659-62
Berger, B J; Dai, W W; Wang, H et al. (1996) Aromatic amino acid transamination and methionine recycling in trypanosomatids. Proc Natl Acad Sci U S A 93:4126-30
Field, H; Cerami, A; Henderson, G B (1992) Cloning, sequencing, and demonstration of polymorphism in trypanothione reductase from Crithidia fasciculata. Mol Biochem Parasitol 50:47-56
Fairlamb, A H; Cerami, A (1992) Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 46:695-729
Henderson, G B; Murgolo, N J; Kuriyan, J et al. (1991) Engineering the substrate specificity of glutathione reductase toward that of trypanothione reduction. Proc Natl Acad Sci U S A 88:8769-73
Kuriyan, J; Kong, X P; Krishna, T S et al. (1991) X-ray structure of trypanothione reductase from Crithidia fasciculata at 2.4-A resolution. Proc Natl Acad Sci U S A 88:8764-8
Henderson, G B; Ulrich, P; Fairlamb, A H et al. (1988) ""Subversive"" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc Natl Acad Sci U S A 85:5374-8
Henderson, G B; Fairlamb, A H; Ulrich, P et al. (1987) Substrate specificity of the flavoprotein trypanothione disulfide reductase from Crithidia fasciculata. Biochemistry 26:3023-7

Showing the most recent 10 out of 14 publications